Reports Q3 revenue EUR2.0M vs. EUR14.9M last year. Anticipates our cash and cash equivalents will support operations into 2025. “We initiated our phase 2 clinical study of acimtamig in combination with AlloNK(R) and received encouraging feedback on the design of our LuminICE-203 trial from the FDA,” said Dr. Adi Hoess, CEO of Affimed. “We also continued to make progress with AFM24 in combination with atezolizumab and advanced AFM28 in the dose escalation. This positions our company well to report further updates on all three clinical programs within the next few months.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AFMD:
- Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
- Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
- Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
- AFMD Earnings this Week: How Will it Perform?
- Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
